Editor: Tommaso Claudio Mineo

Malignant Pleural Mesothelioma: Present Status and Future Directions

eBook: US $99 Special Offer (PDF + Printed Copy): US $228
Printed Copy: US $179
Library License: US $396
ISBN: 978-1-68108-194-6 (Print)
ISBN: 978-1-68108-193-9 (Online)
Year of Publication: 2016
DOI: 10.2174/97816810819461160101


Malignant pleural mesothelioma is a life-threatening neoplasm of the mesothelium, the layer of tissue that covers many organs in the human body. The incidence of this type of neoplasm is gradually increasing among the global human population. Mesothelioma prognosis in patients is usually poor and their life expectancy is significantly reduced. This edited monograph presents holistic information about malignant mesothelioma in one volume. Readers will gain knowledge of the etiology, immunopathology of this disease and will understand the rationale for new treatment methods. The initial section of the book gives the historical context of mesothelioma in medicine. Subsequent sections illustrate mesothelioma epidemiology with respect to the problem of asbestos diffusion in different areas of the world such as Europe, The Americas, East Asia, Australia and Africa. This is followed by chapters detailing current information about asbestos and non-asbestos molecular biology and etiopathogenesis, as well as intriguing insights from human genetics and translational medicine. Other sections in this volume focus on clinical information; mesothelioma diagnosis and staging are thoroughly described with a focus on serum biomarkers and pleural liquid cytology. Additional sections provide information on treatment modalities, with one section dedicated to surgical procedures.

Malignant Pleural Mesothelioma: Present Status and Future Directions is a comprehensive informational resource with well organized sections, aided by protocol charts, tables and figures. The book is essential for both medical oncology students and specialists who want to augment or update their knowledge about this neoplasm.


Mesothelioma remains an unusual cancer that a limited number of centers treat in high volumes across the globe. Industrialized countries are currently experiencing an epidemic of mesothelioma and the incidence is expected to continue to rise for the next decade at least.

The outcome of mesothelioma is poor with an overall median survival ranging between 10 and 20 months. However, due to the rising incidence and poor outcome, the amount of research in the clinical setting and in the laboratory has rapidly expanded over the past 15 years. Hence, it is important that all physicians involved in the care of patients with mesothelioma be familiar with the important issues related to this disease to have a thorough understanding of the tumor biology, staging process, treatment options and the role of multidisciplinary approach.

Currently, cisplatin combined with an anti-folate agent has been recognized as standard of care for non-surgical patients with advanced disease. In the next decade, however, it is very likely that we will see new standards coming forward.

In this book, edited by Professor Mineo, many world renowned contributors in the field of mesothelioma present an update of their research and clinical experience, putting their findings in perspective. This book provides an excellent companion for physicians focusing on mesothelioma research and treatment as well as for individuals who may only see these patients infrequently.

Shaf Keshavjee
University Health Network
Division of Thoracic Surgery
Department of Surgery
University of Toronto